TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01422785
Drug: clindamycin phosphate 1.2%/tretinoin 0.025% gel plus benzoyl peroxide 6% foaming cloths
Approvals — FDA: no, EMA: no, PMDA: no
Description: wash face with the benzoyl peroxide foaming cloth then rinse. then apply clindamycin phosphate 1.2%/tretinoin 0.025% gel. both done in the evening.
Study: NCT01748812
Drug: Osteomalacia
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04410562
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive a bottle containing 19 tablets of placebo. They will be instructed to take two tablets for the first three days and one tablet for the following 11 days.
Study: NCT02912494
Drug: JR-131
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01109121
Drug: Combination 400
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tranilast 300 mg QD; Allopurinol 400 mg QD
Study: NCT01109121
Drug: Combination 600
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tranilast, 300 mg QD; Allopurinol 600 mg QD
Study: NCT01157572
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients with moderate to severe aortic valve insufficiency will be randomized to Placebo
Study: NCT00104416
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo control
Study: NCT01450696
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Capecitabine will be administered at a dose of 800 mg/m\^2 orally twice daily for 14 days q3w for up to 6 cycles (Cycles 1 to 6).
Study: NCT03668496
Drug: The placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: in the control group,placebo was given with Carboplatin and Paclitaxel in the first day of each cycle, with intravenous drip.
Study: NCT00883168
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT00000149
Drug: Beta Blocker
Normalized name: Beta blocker
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04296305
Drug: Placebo Administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given IV after
Study: NCT00505973
Drug: SCA-136
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01804933
Drug: profound neuromuscular blockade
Normalized name: Profender
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rocuronium dose will be infused to maintain a depth of NMB to PTC 1\~2 intraoperatively
Study: NCT00887367
Drug: GSK598809
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two 175 mg doses of GSK598809 will be given.
Study: NCT03668470
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo: one injection per week during 24 weeks
Study: NCT01920919
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00323960
Drug: 3 MPDN pulse + PDN
Normalized name: DULSE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 methylprednisolone pulses followed (30 mg/kg/pulse max 1 gram) followed by prednisone 2 mg/Kg/day to be tapered to 0.2 mg/kg/day in 6 months and then discontinued in 2 years.
Study: NCT02385084
Drug: LY2409021
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally
Study: NCT04664933
Drug: Intra-arterial administration of neuroprotective agents
Normalized name: methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intra-arterial administration of 3-n-butylphthalide for 16 to 24 hours during and after the operation at 17.36 to 26.04 ug/min
Study: NCT02866006
Drug: BVAC-C
Approvals — FDA: no, EMA: no, PMDA: no
Description: Autologous B cells and monocytes transfected with E6E7 gene of HPV
Study: NCT01162824
Drug: Acetylcholine
Normalized name: Acetylcholine
DrugBank: Acetylcholine (DB03128)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Incremental doses of 2, 20 and 100 µg of ACH will be injected into the left coronary artery (LCA) via the diagnostic catheter for 3 minutes each. After that 80 µg of ACH will be injected into the right coronary artery. Coronary angiography will be performed after each 3 minute dose period. After the test or when intolerable chest pain due to coronary spasm occurs, 0.2 mg of glyceryltrinitrate will be injected into each vessel. During the test, heart rate, blood pressure and ECG will be monitored continuously.
Study: NCT01162824
Drug: Adenosine
Normalized name: Adenosine
DrugBank: Adenosine phosphate (DB00131)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Coronary blood flow velocity measurements will be performed in the mid segment of the left anterior descending artery with a 0.014-in intracoronary Doppler guidewire connected to the corresponding interface. Measurements will be obtained after the administration of nitroglycerin, at baseline and during maximal hyperaemia. Sustained intravenous administration of adenosine - an arteriolar vasodilator- will be used to induce maximal hyperaemia (140-180µg/kg/min).
Study: NCT01127464
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comparison of 3 different doses of DCVax-001 administered with poly-ICLC, the administration of poly-ICLC alone, or a placebo control
Study: NCT00479817
Drug: AMG 386 Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: AMG 386 Placebo
Study: NCT00330980
Drug: 40 mg Pravastatin (Pravachol)
Normalized name: pravastatin sodium 40 MG [Pravachol]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive 40 mg of pravastatin for 6 months.
Study: NCT00330980
Drug: 20 mg Simvastatin
Normalized name: simvastatin 20 MG
DrugBank: Simvastatin (DB00641)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants will receive 20 mg of simvastatin for 6 months.
Study: NCT00330980
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive placebo for 6 months.
Study: NCT00256360
Drug: dose dense with neulasta
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03160248
Drug: Placebo Oral Tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: This study aims on investigating the efficacy of Apremilast in nummular eczema patients - placebo controlled
Study: NCT02910752
Drug: CLAM+PBSC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cladribine 5mg/m2 + cytarabine 1.5g/m2 + mitoxantrone 10mg/m2 from D1 to D5
Study: NCT02765815
Drug: Bupivacaine 0.5 % with Epinephrine
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02765815
Drug: Ketorolac 30mg
Normalized name: ketorolac 30 MG
DrugBank: Ketorolac (DB00465)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02765815
Drug: Bupivacaine 0.25% with Epinephrine
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02262026
Drug: 125 mg AZD0530
Approvals — FDA: no, EMA: no, PMDA: no
Description: Randomized to receive 125 mg of AZD0530
Study: NCT02262026
Drug: 50 mg AZD0530
Approvals — FDA: no, EMA: no, PMDA: no
Description: Randomized to receive 50 mg of AZD0530
Study: NCT02262026
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT00019968
Drug: tumor necrosis factor
Normalized name: Tumor necrosis factor
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00869791
Drug: IPX066
Approvals — FDA: no, EMA: no, PMDA: no
Description: experimental drug product: extended-release carbidopa-levodopa capsules
Study: NCT00869791
Drug: IR CD-LD
Normalized name: IR-3535
Approvals — FDA: no, EMA: no, PMDA: no
Description: active comparator: immediate-release carbidopa-levodopa capsules
Study: NCT00800527
Drug: Diclofenac
Normalized name: Diclofenac
DrugBank: Diclofenac (DB00586)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Diclofenac 75 mg one a day up to 30 day
Study: NCT01541904
Drug: PRO-118 Ophthalmic Solution 0.015%
Approvals — FDA: no, EMA: no, PMDA: no
Description: PRO-118 Ophthalmic Solution 0.015 % applied qd during 21 days
Study: NCT01541904
Drug: PRO-118 Ophthalmic Solution 0.015 %
Approvals — FDA: no, EMA: no, PMDA: no
Description: PRO-118 Ophthalmic Solution 0.015 % applied twice to day during 21 days
Study: NCT01541904
Drug: PRO-118 Ophthalmic Solution 0.020 %
Approvals — FDA: no, EMA: no, PMDA: no
Description: PRO-118 Ophthalmic Solution 0.020 % applied qd during 21 days
Study: NCT01541904
Drug: PRO-118 Ophthalmic Solution 0.020 %
Approvals — FDA: no, EMA: no, PMDA: no
Description: PRO-118 Ophthalmic Solution 0.020 % applied twice to day during 21 days
Study: NCT01541904
Drug: Placebo Ophthalmic Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo Ophthalmic Solution applied qd during 21 days
Study: NCT01369472
Drug: Dilatrend SR capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: single oral administration in period 1 or 2, 3 for each sequential group.
Study: NCT03874741
Drug: SCT200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-EGFR monoclonal antibody DDP(75mg/m2),d1; 5-FU(750mg/m2),d1-5, every 21d; PF chemothrapy up to 6 cycles. 6.0mg/kg of SCT200 will be administered once a week for a maximum of 6 cycles. After 6 cycles, 8.0mg/kg of SCT200 will be administered every two weeks until disease progression~Other Names:~• SCT200
Study: NCT02963168
Drug: Oradoxel
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral docetaxel will be supplied in capsules and oral HM30181A-UK tablets
Study: NCT00313144
Drug: ARALAST Alpha1-Proteinase Inhibitor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weekly ARALAST infusions for 2 years, dose and mode of administration as prescribed by the physician
Study: NCT03398031
Drug: Placebo Oral Tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: After biochemical diagnosis of pregnancy each participant will receive placebo tablet once daily till the end of the 1st trimester
Study: NCT01347541
Drug: FDA-Approved Anti-Anxiety Medications
Normalized name: pramoxine hydrochloride Medicated Pad [Scalpicin Anti-Itch]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants assigned to receive the combination therapy may receive one or more of the following medications based on their individual needs: fluoxetine, sertraline, paroxetine, buspirone, propranolol, trazodone, and any of the benzodiazepines. Participants may begin receiving medication immediately or anytime within the 12 months post-injury. Form, dosage, frequency, and duration depend on patient need, but all are prescribed in accordance with standards of care.
Study: NCT01656005
Drug: Beclometasone
Normalized name: Beclometasone
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 puffs bid for final week (week 6) of each treatment arm
Study: NCT00796731
Drug: SAR3419
Approvals — FDA: no, EMA: no, PMDA: no
Description: administered by intravenous infusion
Study: NCT03951831
Drug: REGN2810
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cemiplimab (REGN 2810) is administered starting at week 4 at a dose of 350mg IV every 3 weeks (flat dose) for up to 55 weeks or intolerable side effect or progression of disease.
Study: NCT00253773
Drug: acetominophen, sulfer amino acids; cysteine and methionine
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03718884
Drug: Drug Cocktail
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug cocktail consists of caffeine, warfarin plus vitamin K, omeprazole, dextromethorphan, and midazolam, administered orally
Study: NCT04130230
Drug: Standard therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard therapy for sepsis and septic shock
Study: NCT00382421
Drug: acetylsalicylic acid
Normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01794663
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous infusion for 1 hour at start of transplant procedure
Study: NCT00350870
Drug: disulfiram
Normalized name: Disulfiram
DrugBank: Disulfiram (DB00822)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 250mg per day of Disulfiram plus CBT
Study: NCT00350870
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo plus CBT
Study: NCT00350870
Drug: Disulfiram plus Contingency Management
Normalized name: Disulfiram
DrugBank: Disulfiram (DB00822)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 250mg of Disulfiram plus Contingency Management for cocaine abstinence and medication compliance plus CBT.
Study: NCT03136146
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT03783442
Drug: Fluorouracil (5-FU)
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Administered IV
Study: NCT03783442
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Administered orally
Study: NCT03783442
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo to match Tislelizumab
Study: NCT04116411
Drug: Placebo oral tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo treatment of glioblastoma
Study: NCT00675623
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo three times daily for six months
Study: NCT01527279
Drug: 0.9% saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients assigned to control group will be administered 0.9% saline in boluses of 10cm3 every 5 minutes up to cumulative volume of 50cm3, conversion of AF to SN or in case of serious adverse event or conversion of AF to different supraventricular arrhythmia. BP will be measured before every injection.
Study: NCT00323492
Drug: Current HAART regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maintain baseline regimen
Study: NCT00093899
Drug: ezetimibe (+) simvastatin
Normalized name: ezetimibe / simvastatin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Duration of Treatment: 6 months
Study: NCT03042429
Drug: Cycles N8, N5 and N6
Approvals — FDA: no, EMA: no, PMDA: no
Description: two chemotherapy cycles N8 followed by standard arm therapy
Study: NCT01480583
Drug: GRN1005
Approvals — FDA: no, EMA: no, PMDA: no
Description: 550 mg/m2 IV every 3 weeks
Study: NCT02620800
Drug: 5FU
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 5 fluorouracil (5-FU) (180 mg/m\^2/day for 14 days) by CIVI via ambulatory pump
Study: NCT02620800
Drug: calcium leucovorin
Normalized name: Calcium leucovorin
Approvals — FDA: no, EMA: no, PMDA: no
Description: calcium leucovorin (20 mg/m\^2) IV bolus, on Days 1, 8, 15
Study: NCT02997696
Drug: Placebo matching ONO-4474
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01555970
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Week 1: one capsule twice a day Week 2: two capsules twice a day Weeks 3-16: two capsules in the morning and 3 in the evening
Study: NCT01130909
Drug: AZD6765
Approvals — FDA: no, EMA: no, PMDA: no
Description: 75 mg
Study: NCT01130909
Drug: AZD6765
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 mg
Study: NCT01130909
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 125 mL sterile NaCl 0.9%
Study: NCT03989349
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT00943098
Drug: Diclofenac HPBCD s.c. 75mg/ml
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 single injection at day of dental surgical extraction
Study: NCT00943098
Drug: Voltarol 75mg/3ml i.m.
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 single injection at day of dental surgical extraction
Study: NCT03404063
Drug: Cardiac Drug
Normalized name: Leonurus cardiaca extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients in the AMI trial will receive one dose of IMP during the index procedure. The IMP administration will be performed by dedicated catheter into infarct related artery.~Active IMP consist of 30 000 000 of Wharton's jelly mesenchymal stem cells (WJMSCs) in each IMP dose prepared for patients randomized into active treatment group.
Study: NCT03404063
Drug: Placebos
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients randomized to the control group will receive 0.9% NaCl and 5% albumin injections (in the same volume as CardioCell) in the same manner.~Control group will receive the same amount of fluid used for WJMSCs preparation, without cells.
Study: NCT02524275
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given PO
Study: NCT00050206
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02065843
Drug: Mulungu
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg/single dose/1 hour before dental surgery
Study: NCT02065843
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg/single dose/1 hour before dental surgery
Study: NCT00420082
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Encapsulated Placebo tablets Q.D.
Study: NCT03515733
Drug: Placebo Oral Tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablet, identical appearance to experimental tablet
Study: NCT04041544
Drug: SN1011
Approvals — FDA: no, EMA: no, PMDA: no
Description: SN1011 will be supplied to the Pharmacy as 25 mg and 100 mg capsules.
Study: NCT04041544
Drug: SN1011 placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: The placebo to be used in this study will be identical to SN1011, minus the active ingredient.
Study: NCT00729495
Drug: celecoxib
Normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: dose form
Study: NCT02850419
Drug: ThermoDox (Thermally Sensitive Liposomal Doxorubicin)
Approvals — FDA: no, EMA: no, PMDA: no
Description: A dose of 40 mg/m2 will be administered at each cycle for a total of 6 cycles. ThermoDox will be administered in conjunction with hyperthermia.
Study: NCT03315793
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally
Study: NCT01787396
Drug: Placebo(Metformin)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01787396
Drug: Placebo(Gemigliptin)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02712983
Drug: TIP
Normalized name: Q-Tips
Approvals — FDA: no, EMA: no, PMDA: no
Description: TIP dose regimen
Study: NCT02712983
Drug: TIP and placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: TIP and inhaled placebo dose regimen
Study: NCT02712983
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled placebo dose regimen
Study: NCT03173976
Drug: Zoledronic Acid
Normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Zoledronic acid, a member of bisphosphonate class, inhibits bone resorption.
Study: NCT00283803
Drug: Antiandrogen
Normalized name: Antiandrogen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hormonal therapy used as lead in treatment with luteinizing hormone-releasing hormone (LHRH) agonist to prevent the initial rise in testosterone (testosterone flare) seen during the first dose of LHRH agonists.
Study: NCT00479505
Drug: UK-369,003
Approvals — FDA: no, EMA: no, PMDA: no
Description: UK-369,003 100mg, 50mg, 25mg and 10mg doses in addition to placebo.
Study: NCT00479505
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT02428751
Drug: Pegylated liposomal doxorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg/m2, IV (in the vein) on day 1 of each 21 day cycle
Study: NCT02428751
Drug: Doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 50 mg/m2, IV (in the vein) on day 1 of each 21 day cycle
Study: NCT00721760
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.4 mL (0.2 mL if SRI) solution in ready-to-use 0.5 ml prefilled syringe strictly identical in appearance but without active component~Subcutaneous injection
Study: NCT02679144
Drug: Difluoromethylornithine (DFMO)
Normalized name: α-difluoromethylornithine
DrugBank: Eflornithine (DB06243)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subjects will receive 730 Days of oral difluoromethylornithine (DFMO) at a dose of 750 mg/m2 ± 250 mg/m2 BID (strata 1, 2, 3, and 4) OR 2500 mg/m2 BID (stratum 1B) on each day of study.
Study: NCT00559455
Drug: Fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 400mg/m², 2 hours IV bolus, Day 1; 22 hours continuous IV infusion 600mg/m², Day 1 and Day 2; Every 2 weeks
Study: NCT00559455
Drug: Leucovorin
Normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 200mg/m², Day 1 and Day 2; Every 2 weeks
Study: NCT00093197
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03883347
Drug: Remifentanil
Normalized name: Remifentanil
DrugBank: Remifentanil (DB00899)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous administration of remifentanil 1 mcg / kg within 10 minutes prior to regional anesthesia and 0.025 mcg / kg / h after performing regional anaesthesia until the end of the surgery
Study: NCT01340625
Drug: Norethindrone/Ethinyl Estradiol
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.4 mg/35 mcg Chewable Tablets
Study: NCT01340625
Drug: Ovcon® 35 Fe
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.4 mg/35 mcg Chewable Tablets
Study: NCT01162954
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00182715
Drug: capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00182715
Drug: fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00182715
Drug: leucovorin calcium
Normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00053976
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00606541
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT01110330
Drug: Placebo cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: A topical, white, homogenous cream identical in appearance to study drug applied sparingly to all affected areas of the foot (or feet), once daily (at night or in the evenings) for a total of 4 weeks.
Study: NCT04925076
Drug: Ethanol
Normalized name: Ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: A beverage containing dose of ethanol individually determined to raise a participant's breath alcohol concentration up to approximately 0.08 g/dL.
Study: NCT01361763
Drug: Antiplatelets
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100mg once a day
Study: NCT00368381
Drug: Hydrocortisone
Normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Patients randomized to this arm will receive hydrocortisone for the treatment of adrenal insufficiency secondary to sepsis.
Study: NCT03388866
Drug: Mite extract sublingual immunotherapy (SLIT)
Normalized name: mite extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administration of increasing weekly doses of extracts of mites Dermatophagoides pteronyssinus in the treatment group.